Kymera Therapeutics (KYMR) reported a Q1 net loss Friday of $0.82 per diluted share, widending from a $0.69 loss a year earlier.
Analysts polled by FactSet expected a loss of $0.88.
Collaboration revenue for the quarter ended March 31 was $22.1 million, compared with $10.3 million a year earlier.
Analysts polled by FactSet expected $10.7 million.
Kymera shares were up 1.6% in recent premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。